Annuncio • 1h
Lanxess A.G. Appoints Uta Kemmerich-Keil as A Member of the Supervisory Board, Effective May 21, 2026 British American Tobacco p.l.c. announces that with effect from 21 May 2026, Uta Kemmerich-Keil, a Non-Executive Director of the Company, has been appointed as a member of the Supervisory Board of Lanxess A.G., a company listed on the Frankfurt Stock Exchange. Declared Dividend • May 20
Dividend of €0.10 announced Dividend of €0.10 is the same as last year. Ex-date: 22nd May 2026 Payment date: 27th May 2026 Dividend yield will be 0.5%, which is lower than the industry average of 3.0%. Annuncio • Apr 11
LANXESS Aktiengesellschaft, Annual General Meeting, May 22, 2025 LANXESS Aktiengesellschaft, Annual General Meeting, May 22, 2025, at 10:00 W. Europe Standard Time. Annuncio • Apr 02
UBE Corporation (TSE:4208) completed the acquisition of Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for approximately €500 million. UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million on October 3, 2024. For the last twelve months period ending September 30, 2024, Urethane Systems Business of LANXESS reported total revenue of €265 million and EBITDA of €50 million. The acquisition price is expected to be confirmed based on the price adjustment indicated in the stock purchase agreement. The acquisition will be financed through cash on hand and interest-bearing debt. The Urethane Systems business comprises 5 manufacturing sites globally as well as application laboratories in the USA, Europe and China. UBE Corporation will take over all operations from LANXESS with a total of around 400 employees. LANXESS will use the proceeds to reduce its net debt. The transaction is subject to the approval of the relevant authorities including regulatory approval. The transaction is expected to close in the first half of 2025. Nomura Holding America, Inc. acted as financial advisor to UBE Corporation. Matthias Töke, Katharina Spenner LL.M., Joachim Fröhlich LL.M., Katharina Weiner, Daniel Bork, Christoph Becker, Ariane Schaaf, Simone (Bach) Rieken LL.M., Johannes M. Baumann, LL.M., Christian Atzler, Christian Vocke, Richard Raoul Stefanink, Patrick H. Wilkening, Markus Hecht, Christian Reichel and Nicolas Kredel LL.M. of Baker & Mckenzie Partnerschaft Von Rechtsanwälten Wirtschaftsprüfern,Steuerberatern Und Solicitors acted as legal advisor to UBE Corporation. Masahiro Inaba, Byron Frost and Tetsuo Tsujimoto of Baker & McKenzie (Gaikokuho Joint Enterprise) acted as legal advisor to UBE Corporation.
UBE Corporation (TSE:4208) completed the acquisition of Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for approximately €500 million on April 1, 2025. All relevant antitrust authorities had granted the necessary approvals for the transaction Annuncio • Mar 22
LANXESS Aktiengesellschaft announces Annual dividend, payable on May 27, 2025 LANXESS Aktiengesellschaft announced Annual dividend of EUR 0.1000 per share payable on May 27, 2025, ex-date on May 23, 2025 and record date on May 26, 2025. Annuncio • Oct 04
UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million. UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million on October 3, 2024. For the last twelve months period ending September 30, 2024, Urethane Systems Business of LANXESS reported total revenue of €265 million and EBITDA of €50 million. The acquisition price is expected to be confirmed based on the price adjustment indicated in the stock purchase agreement. The acquisition will be financed through cash on hand and interest-bearing debt. The Urethane Systems business comprises 5 manufacturing sites globally as well as application laboratories in the USA, Europe and China. UBE Corporation will take over all operations from LANXESS with a total of around 400 employees. LANXESS will use the proceeds to reduce its net debt. The transaction is subject to the approval of the relevant authorities including regulatory approval. The transaction is expected to close in the first half of 2025. Annuncio • Jul 10
LANXESS Aktiengesellschaft Announces Executive Changes Lanxess Corp. announced Simon Berheide as its new regional CFO for North America. Berheide is a 14-year veteran of Lanxess at its global headquarters in Germany and was most recently head of business development and integration as well as head of global controlling and strategy. He'll be in charge of the financial operation of Lanxess' 28 locations in the U.S., Canada and Mexico. He succeeds Christian Meiners, who is returning to Germany after three years in Pittsburgh to work in Lanxess' Advanced Industrial Intermediates. Berheide has moved as of July 1 to the Pittsburgh region with his family, and he is working with Lanxess' new president and CEO, Frederique van Baarle. Van Baarle took over in October. Berheide, fluent in German and English, had been in a dual degree training program at Bayer and also had an MBA at IE Business School in Spain and the Stern School of Business at New York University. Reported Earnings • Mar 17
Full year 2023 earnings released: €9.76 loss per share (vs €2.13 profit in FY 2022) Full year 2023 results: €9.76 loss per share (down from €2.13 profit in FY 2022). Revenue: €6.71b (down 17% from FY 2022). Net loss: €843.0m (down €1.03b from profit in FY 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Annuncio • Jan 16
Lanxess Reportedly Seeks to Sell Polyurethane Ops LANXESS Aktiengesellschaft (XTRA:LXS) has initiated a process to sell its polyurethane business, which could be valued at between EUR 500 million (USD 547.2 million) and EUR 600 million, German paper Handelsblatt reported on January 15, 2024. The company has engaged Deutsche Bank to search for a buyer, Handelsblatt said, citing people familiar with the matter. Chemical companies such as Evonik Industries AG (XTRA:EVK), Stockmeier, or Plixxent, are considered possible interested parties. With the sale, Lanxess aims to completely exit the plastics market as the company has transformed into a producer of ingredients for food, cosmetics, and pharmaceuticals. Reported Earnings • Nov 09
Third quarter 2023 earnings released: €1.52 loss per share (vs €0.97 profit in 3Q 2022) Third quarter 2023 results: €1.52 loss per share (down from €0.97 profit in 3Q 2022). Revenue: €1.60b (down 27% from 3Q 2022). Net loss: €131.0m (down 256% from profit in 3Q 2022). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Annuncio • Nov 07
LANXESS Aktiengesellschaft Proposes Dividend for the Fiscal Year 2023 LANXESS Aktiengesellschaft proposed dividend of EUR 0.10 for the Fiscal Year 2023. Annuncio • Sep 18
LANXESS Aktiengesellschaft(XTRA:LXS) dropped from FTSE All-World Index (USD) LANXESS Aktiengesellschaft(XTRA:LXS) dropped from FTSE All-World Index (USD) New Risk • Sep 14
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Shares are highly illiquid. Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 283% Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. New Risk • Aug 08
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 283% Dividend yield: 3.6% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Shares are highly illiquid. Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 283% Reported Earnings • Aug 05
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: €1.78b (down 11% from 2Q 2022). Net loss: €145.0m (down 402% from profit in 2Q 2022). Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance. Buying Opportunity • Jun 21
Now 32% undervalued after recent price drop Over the last 90 days, the stock is down 23%. The fair value is estimated to be €39.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 56%. For the next 3 years, revenue is forecast to grow by 1.6% per annum. Earnings is also forecast to grow by 30% per annum over the same time period. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €26.75, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €42.60 per share. Upcoming Dividend • May 18
Upcoming dividend of €1.05 per share at 3.0% yield Eligible shareholders must have bought the stock before 25 May 2023. Payment date: 30 May 2023. Payout ratio is a comfortable 71% and the cash payout ratio is 97%. Trailing yield: 3.0%. Lower than top quartile of British dividend payers (5.8%). Higher than average of industry peers (2.4%). Reported Earnings • May 11
First quarter 2023 earnings released: EPS: €0.12 (vs €0.76 in 1Q 2022) First quarter 2023 results: EPS: €0.12 (down from €0.76 in 1Q 2022). Revenue: €1.90b (down 1.7% from 1Q 2022). Net income: €10.0m (down 85% from 1Q 2022). Profit margin: 0.5% (down from 3.4% in 1Q 2022). Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 17
Full year 2022 earnings released: EPS: €2.13 (vs €2.54 in FY 2021) Full year 2022 results: EPS: €2.13 (down from €2.54 in FY 2021). Revenue: €8.09b (up 7.0% from FY 2021). Net income: €184.0m (down 16% from FY 2021). Profit margin: 2.3% (down from 2.9% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €35.06, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €50.25 per share. Buying Opportunity • Mar 06
Now 20% undervalued Over the last 90 days, the stock is up 16%. The fair value is estimated to be €54.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has declined by 21%. For the next 3 years, revenue is forecast to grow by 1.9% per annum. Earnings is also forecast to grow by 16% per annum over the same time period. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improved over the past week After last week's 19% share price gain to €43.16, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 15x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €56.00 per share. Valuation Update With 7 Day Price Move • Sep 24
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €31.12, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 40% over the past three years. Reported Earnings • Aug 08
Second quarter 2022 earnings released: EPS: €0.56 (vs €0.54 in 2Q 2021) Second quarter 2022 results: EPS: €0.56 (up from €0.54 in 2Q 2021). Revenue: €2.00b (up 36% from 2Q 2021). Net income: €48.0m (up 2.1% from 2Q 2021). Profit margin: 2.4% (down from 3.2% in 2Q 2021). Over the next year, revenue is expected to shrink by 8.4% compared to a 21% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 18% share price gain to €44.69, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 4.4% over the past three years. Upcoming Dividend • May 19
Upcoming dividend of €1.05 per share Eligible shareholders must have bought the stock before 26 May 2022. Payment date: 31 May 2022. Payout ratio is a comfortable 36% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of British dividend payers (4.8%). In line with average of industry peers (2.8%). Reported Earnings • May 06
First quarter 2022 earnings released: EPS: €1.13 (vs €0.73 in 1Q 2021) First quarter 2022 results: EPS: €1.13 (up from €0.73 in 1Q 2021). Revenue: €2.43b (up 44% from 1Q 2021). Net income: €98.0m (up 56% from 1Q 2021). Profit margin: 4.0% (up from 3.7% in 1Q 2021). Over the next year, revenue is forecast to grow 6.9% compared to a 17% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 15
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Revenue: €7.56b (up 24% from FY 2020). Net income: €219.0m (down 75% from FY 2020). Profit margin: 2.9% (down from 15% in FY 2020). Revenue exceeded analyst estimates by 3.9%. Over the next year, revenue is forecast to grow 9.4% compared to a 12% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 25
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €44.04, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 19x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 4.9% over the past three years. Reported Earnings • Aug 13
Second quarter 2021 earnings released: EPS €0.89 (vs €9.32 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: €1.83b (up 28% from 2Q 2020). Net income: €77.0m (down 90% from 2Q 2020). Profit margin: 4.2% (down from 56% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • May 13
First quarter 2021 earnings released The company reported a poor first quarter result with weaker earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: €1.69b (flat on 1Q 2020). Net income: €63.0m (down 3.1% from 1Q 2020). Profit margin: 3.7% (down from 3.8% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 13
Upcoming dividend of €1.00 per share Eligible shareholders must have bought the stock before 20 May 2021. Payment date: 24 May 2021. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (4.1%). In line with average of industry peers (1.6%). Reported Earnings • Mar 12
Full year 2020 earnings released: EPS €10.30 (vs €2.89 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €6.10b (down 10% from FY 2019). Net income: €892.0m (up 250% from FY 2019). Profit margin: 15% (up from 3.7% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Analyst Estimate Surprise Post Earnings • Mar 12
Revenue beats expectations Revenue exceeded analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 5.7% compared to a 8.5% decline forecast for the Chemicals industry in the United Kingdom. Is New 90 Day High Low • Mar 09
New 90-day high: €66.52 The company is up 8.0% from its price of €61.86 on 09 December 2020. The British market is up 4.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €41.90 per share. Is New 90 Day High Low • Jan 14
New 90-day high: €64.13 The company is up 27% from its price of €50.50 on 16 October 2020. The British market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €49.27 per share. Is New 90 Day High Low • Dec 28
New 90-day high: €63.97 The company is up 28% from its price of €49.91 on 29 September 2020. The British market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €66.51 per share. Is New 90 Day High Low • Dec 08
New 90-day high: €60.88 The company is up 21% from its price of €50.42 on 09 September 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €64.31 per share.